Real-world survival, cognitive, and quality of life outcomes of methotrexate/ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma
Warayoot Luangmaneerote, Natrada Rattanapong, Anthipa Chokesuwattanaskul, Tassapong Raiyawa, Thunyamon Chajuwan, Pitchayaporn Jongdee, Ponlapat Rojnuckarin, Chantiya Chanswangphuwana · 2025
Read Real-world survival, cognitive, and quality of life outcomes of methotrexate/ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma by Warayoot Luangmaneerote, Natrada Rattanapong, Anthipa Chokesuwattanaskul, Tassapong Raiyawa, Thunyamon Chajuwan, Pitchayaporn Jongdee, Ponlapat Rojnuckarin, Chantiya Chanswangphuwana (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12703023.txt.
Description
Warayoot Luangmaneerote and co-authors report real-world outcomes for a rare brain lymphoma treated where top care is scarce. Their 2025 study covers primary central nervous system lymphoma, newly found in 94 patients from 2011 to 2024. Rich settings favor strong drug rounds plus stem cell transplant.
In this center, high-dose drugs plus whole brain radiation form the local standard. One group of 56 patients got a two-drug round, and a second group got the main drug alone. The team tracks survival with standard models. Separate tests compare thinking skills and life quality in patients in remission against matched lymphoma peers. The data show what the local standard achieves outside trial settings.
Catalog record
| CREATOR | Warayoot Luangmaneerote, Natrada Rattanapong, Anthipa Chokesuwattanaskul, Tassapong Raiyawa, Thunyamon Chajuwan, Pitchayaporn Jongdee, Ponlapat Rojnuckarin, Chantiya Chanswangphuwana |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |